COVID-19; A platform for real change?
Since lockdown ensued pretty much across the Globe (as at 28 April it was estimated a third of the 7.8bn global population was under some...
Life Sciences
About Me
Corporate Partner at DLA Piper and a member of the firm's Life Sciences sector. I am an honorary lecturer at the University of Birmingham and member of the London Stock Exchange's Regional Advisory Group. Specialising in capital markets advising on IPOs (both on the London Stock Exchange's Main Market and AIM), secondary offerings, takeovers and mergers and public company corporate governance/ESG. I am also active in M&A transactions (acting for both private and public companies with a particular focus on cross-border transactions), joint ventures and early-stage investments (VC, spin-outs etc).
Robert Newman's Passles
Most Read
Most Shared
UK plays catch-up in medicinal cannabis market
1 November 2018 marks a turning point in relation to the use of medicinal cannabis in the UK. The Misuse of Drugs (Amendments) (Cannabis...
The Biomedical Bubble debate
The FT commented earlier today on the highly provocative report "The Biomedical Bubble" published by Nesta, the charity which, in its own...
Was the acquisition of PillPack inevitable and a sign of what is to come?
Two weeks after a certain tech giant announced its reported $1 billion acquisition of PillPack, I consider whether this move by the...
Government must do more to implement the Life Sciences Industrial Strategy
If anyone wondered why have a two-house system of parliament, perhaps a good starting point would be to read the opinion of the Science...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net